Abstract
According to domestic and foreign publications, benign prostatic hyperplasia (BPH) is one of the most common urological diseases among older men, which prevalence reaches 50% by the age of 60.To analyze the efficiency of the use of the alpha1-blocker silodosin at a dose of 8 mg a day in comorbid patients with lower urinary tract symptoms (LUTS), associated with BPH.A total of 197 comorbid patients with LUTS/BPH were included in the study. All men underwent a standard examination. They were divided into 2 groups without differences in baseline parameters. In the main group (n=100) patients received silodosin at a dose of 8 mg, while in the control group 97 men did not receive any drug therapy for LUTS.There were significant differences between groups in the total IPSS score, postvoid residual (ml), maximum urine flow rate (ml/s), patient satisfaction with treatment efficacy based on the TS-VAS visual analogue scale (total score). However, we didnt find significant differences in rate of cardiovascular side effects between the groups.Treatment of comorbid patients with LUTS/BPH with silodosin at a dose of 8 mg results in significant improvement and is not associated with cardiovascular adverse events.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
